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Summary
Epidemiological studies have À rmly identiÀ ed low plasma levels of high-density lipoprotein-
cholesterol (HDL-C) as a strong and independent risk factor for coronary heart disease. 
Cardioprotective effects of HDL particles have been attributed to several mechanisms, 
which primarily reÁ ect their capacity to efÁ ux cellular cholesterol, resulting in the 
transport of cholesterol from peripheral tissues to the liver in the process of reverse 
cholesterol transport. Moreover, HDL equally displays antioxidative, anti-inÁ ammatory, 
cytoprotective, vasodilatory, antithrombotic and anti-infectious properties, all of which are 
capable of contributing to HDL-mediated atheroprotection. It is essential to recognize that 
the plasma HDL fraction is structurally and functionally diverse and consists of multiple, 
highly dynamic subpopulations of particles which differ in biological activities. Evaluation of 
both HDL particle proÀ le and functional heterogeneity are therefore essential to adequately 
assess antiatherogenic properties of HDL. This review summarizes current knowledge about 
the metabolism, structure and composition of HDL subpopulations isolated by different 
experimental approaches, focussing on multiple biological activities of HDL.
© 2011 Elsevier Masson SAS. All rights reserved.
Résumé
Les études épidémiologiques ont clairement identiÀ é de faibles taux plasmatiques de 
HDL-cholestérol (HDL-C) comme de puissants facteurs de risques des maladies coronaires. 
Les mécanismes des effets cardio-protecteurs des HDL sont variés, mais reÁ ètent 
principalement leur rôle dans le transport inverse du cholestérol, c’est-à-dire la capacité 
KEYWORDS
High-density 
lipoprotein; 
Subpopulations; 
Biological activity; 
Function; 
Dysfunction; 
Atherosclerosis
MOTS CLÉS
Lipoprotéine 
de haute densité ; 
Functionality of HDL particles 259
particles [4]. In such small discoid HDL, two molecules of 
apoA-I adopt a “double belt” orientation with their helixes 
oriented parallel to the plane of the disc and perpendicular to 
the lipid acyl chains in such a way that they wrap around the 
lipid bilayer disc forming two stacked rings in an antiparallel 
orientation. Furthermore, apoA-I molecules appear to slide in 
relation to each other between two stable conformations [3]. 
These discoid HDL particles acquire additional free choles-
terol from peripheral tissues, which is then subsequently 
esteriÀ ed to cholesteryl esters by the HDL-associated enzyme 
lecithin: cholesterol acyltransferase (LCAT), generating 
spherical HDL [4]. Cholesteryl ester transfer protein (CETP) 
transfers cholesteryl esters from HDL to apoB-containing 
lipoproteins in exchange for triglycerides [5]. The lipolytic 
enzymes hepatic lipase and endothelial lipase hydrolyse HDL 
triglycerides and phospholipids and generate small spherical 
HDL particles [6]. In spherical HDL, all apoA-I molecules are 
bent to allow their arrangement in identical double belt 
structures [3]. In the case of three mol apoA-I/mol HDL, 
each molecule is bent 60° with inÁ ection points in helices 
5 and 10, forming a trefoil [3]. ApoA-I present in mature 
HDL is catabolized by the liver, whereas lipid-poor apoA-I is 
catabolized by the kidneys.
The complexity of HDL metabolism results in the 
formation of multiple HDL subpopulations which differ in 
density, size, charge and composition. HDL heterogeneity 
can be assessed using several experimental approaches; 
the resulting HDL particle proÀ le is critically determined 
by the method employed [7]. Historically, ultracentrifuga-
tion was the À rst approach applied to lipoprotein isolation 
and subfractionation according to density [7]. Two HDL 
subpopulations were initially characterized, termed HDL2 
(d 1.063-1.125g/ml), large, light, lipid-rich HDL subfraction 
with a mean size of 9-10 nm, and HDL3 (d 1.125-1.21g/ml), 
small dense, lipid-poor HDL subfraction with a mean size of 
8-9nm. Further development of this approach, based on an 
isopycnic equilibrium, allows reproducible fractionation of 
À ve HDL particle subpopulations, large, light HDL2b and 2a, 
and small, dense HDL3a, 3b and 3c, from human plasma in 
a highly puriÀ ed form [7]. The size of HDL particles isolated 
by this approach is progressively reduced with increase in 
hydrated density, in parallel with progressive elevation in 
protein content and in surface/core ratio accompanied by 
diminution in core lipid content.
HDL subpopulations can also be separated based on 
size and charge. An electrophoretic method involving 
Introduction
Several prospective epidemiological studies have found 
that low serum high-density lipoprotein-cholesterol (HDL-C) 
concentrations (deÀ ned as <40mg/dl in both sexes, or as 
<40mg/dl in men and <50mg/dl in women) constitue a strong, 
independent risk factor for coronary heart disease (CHD); 
indeed, CHD risk is elevated by 3% in women and 2% in men 
for each decrement of 1mg/dl in HDL-C [1]. HDL particles 
are distinguished from atherogenic apolipoprotein (apo) 
B-containing lipoproteins by their capacity to exert a wide 
spectrum of anti-atherogenic biological activities, including 
(i) capacity to mediate cellular cholesterol efÁ ux by acting 
as primary acceptors, thereby facilitating reverse cholesterol 
transport (RCT) from the arterial wall and peripheral tissues 
to the liver, (ii) protection of LDL against oxidative stress, 
(iii) anti-inÁ ammatory actions on arterial wall cells, and (iv) 
cytoprotective, (v) vasodilatory, (vi) antithrombotic and (vii) 
anti-infectious actions [2]. This review focuses on current 
knowledge of functionality of plasma HDL particles, with an 
emphasis on its heterogeneity and potential relevance to 
cardiovascular disease.
Structure, composition 
and heterogeneity of plasma HDL
Plasma HDL (hydrated density, 1.063-1.21g/ml) is a hetero-
geneous group of discoid and spherical particles that differ in 
their physico-chemical properties, intravascular metabolism 
and biological activity [2]. Discoid HDLs include small, lipid-
poor, nascent particles made up of apolipoproteins embedded 
in a lipid monolayer of phospholipids and free cholesterol. 
Spherical HDL particles are larger, mature particles that addi-
tionally contain a hydrophobic core of cholesteryl esters and 
triglycerides. The main protein component of HDL is apoA-I 
which plays a key role in the biogenesis and functions of HDL.
ApoA-I is synthesized by both the liver and the intes-
tine. The predominant part of apoA-I molecule, apart from 
the N-terminus of 44 amino acids, is organized into eight 
alpha-helical amphipathic domains of 22 amino acids and 
two repeats of 11 amino acids [3]. ApoA-I is secreted as a 
lipid-poor protein, and then rapidly acquires phospholipids 
and free cholesterol from the same tissues via the ATP 
binding cassette (ABC) A1 transporter to form discoid HDL 
des HDL à transporter le cholestérol des cellules périphériques vers le foie. Les HDL 
ont également des propriétés anti-oxydantes, anti-inÁ ammatoires, cytoprotectrices, 
vasodilatatrices, anti-thrombotiques et anti-infectieuses, qui contribuent au rôle athéro-
protecteur des HDL. Il est cependant indispensable d’avoir à l’esprit que les particules 
HDL circulantes sont très hétérogènes aussi bien dans leurs propriétés physico-chimiques 
que dans leurs activités biologiques. Ainsi, la détermination de la relation entre structure 
et activité des sous-fractions d’HDL est essentielle à l’évaluation de leurs propriétés 
anti-athérogènes. Une première partie de cette revue sera consacrée au métabolisme, 
à la structure et à la composition des sous-fractions d’HDL, séparées par différentes 
techniques. Leurs activités biologiques seront développées dans un deuxième temps.
© 2011 Elsevier Masson SAS. Tous droits réservés.
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Interestingly, the ratios of free cholesterol to cholesteryl 
esters and sphingomyelin to phosphatidylcholine decrease 
with increase in hydrated density of HDL subfractions [10]. 
In addition, minor bioactive lipid components such as sphin-
gosine-1-phosphate (S1P) are preferentially associated with 
dense HDL3 particles [10].
Functionality of HDL particles
HDL particles possess multiple anti-atherogenic and vasopro-
tective activities which include cellular cholesterol efÁ ux 
capacity together with antioxidative, anti-inÁ ammatory, 
cytoprotective, immunosuppressive, vasodilatory, antithrom-
botic and anti-infectious activities [11,12] (Fig. 1).
The multitude of HDL functions should, at least in part, 
result from the wide variety of proteins carried by HDL; 
indeed, different biological activities of HDL appear to be 
mediated by distinct proteins [9,13]. Such compositional 
heterogeneity thereby suggests a high level of functional 
heterogeneity among HDL particles [14,15]. The multiple 
biological functions of HDL may be therefore mediated by 
distinct particle subspecies deÀ ned by speciÀ c clusters of 
bound proteins [13].
two-dimensional electrophoresis allows separation of more 
than 10 HDL subspecies in which spherical D-HDL predomi-
nate [7]. In this approach, HDL particles are À rst fractionated 
by charge in agarose gels into pre-E, D, and pre-D mobility 
particles which are subsequently separated by size in poly-
acrylamide gels and stained using an anti-apoA-I antibody. 
Five major HDL subpopulations identiÀ ed by this approach 
include very small discoid pre-E1 HDL (size about 5.6nm) 
containing apoA-I and phospholipid, very small discoid 
D4 HDL (size about 7.4nm) containing apoA-I, phospholipid 
and free cholesterol, small spherical D3 HDL (size about 8.0 
nm) medium spherical D2 HDL (size about 9.2nm) containing 
apoA-I, apoA-II, phospholipid, free cholesterol, cholesteryl 
ester and triglyceride, and large spherical D1 HDL containing 
apoA-I, phospholipid, free cholesterol, cholesteryl ester and 
triglyceride [7]. Minor HDL subpopulations observed by 2D 
electrophoresis include pre-D particles which do not contain 
apoA-II, large pre-E2 HDL, very large pre-E HDL containing 
apoE without apoA-I and small HDL containing apoA-IV 
without apoA-I.
A novel gas-phase differential electrophoretic macromo-
lecular mobility-based method termed “ion mobility” allows 
direct quantiÀ cation of lipoprotein particle size and concen-
trations [7]. This rapid procedure allows characterisation and 
quantiÀ cation of large, medium and small HDL. HDL particle 
size is equally employed as a basis for a NMR spectroscopy 
approach, which takes advantage of the observation that 
the terminal lipid methyl group proton signal emitted by 
lipoprotein particles is modulated by lipoprotein size as a 
result of differences in local magnetic À elds [7].
The protein component of HDL consists mainly of 
apoA-I (~70%) and apoA-II (~20%). HDL can therefore be 
separated into two primary subclasses according to their 
apolipoprotein composition, those containing only apoA-I 
(LpA-I) and those containing both apoA-I and apoA-II (LpA-I: 
A-II) [7]. LpA-I and LpA-I: A-II contain approximately 35% 
and 65% of plasma apoA-I, respectively. On the other hand, 
approximately half of HDL particles contain apoA-II. HDL 
particles carry a large number of additional proteins at 
considerably lower abundance than apoA-I and apoA-II, 
including apoA-IV, apoC-I, apoC-II, apoC-III, apoE, together 
with enzymes and lipid transfer proteins including LCAT, 
CETP, phospholipid transfer protein (PLTP), paraoxonase 
(PON) and platelet-activating factor-acetyl hydrolase 
(PAF-AH). Recent proteomic analyses allow identiÀ cation 
and quantiÀ cation of 50 or more proteins in ultracentri-
fugally isolated HDL [8,9]. Interestingly, initial analyses 
of the HDL proteome reveal that the abundance of most 
of HDL-associated proteins is insufÀ cient to allow one 
copy per HDL particle, thereby suggesting that speciÀ c 
proteins may be conÀ ned to distinct HDL subpopulations 
of distinct origin and function, which are differentially 
distributed across the HDL particle spectrum. The most 
interesting of these distributions identiÀ es small, dense 
HDL3c as a particle subpopulation in which 7 proteins occur 
predominantly, notably apoJ, apoL-1, apoF, PON 1/3, PLTP 
and PAF-AH [9]. On the other hand, apoE, apoC-I, apoC-II 
and apoC-III preferentially localise to large, light HDL2 [9].
In addition to differences in bound proteins, HDL 
subpopulations may also differ in their content of lipids. 
Figure 1. Major biological activities of HDL. (1) Cholesterol 
efÁ ux capacity (as cholesterol and phospholipids efÁ ux from 
macrophages to small, dense HDL through ABCA1 transporter and 
to large, light HDL through ABCG1 transporter and SR-BI receptor). 
(2) Antioxidative activity (as inhibition of LDL oxidation by one-
electron oxidants and removal of oxidised lipids from oxidised LDL 
predominantly by small, dense HDL). (3) Anti-inÁ ammatory activity 
(as inhibition of cell adhesion molecule expression on endothelial 
cells and inhibition of monocyte adhesion to the endothelium 
predominantly by small, dense HDL). (4) Cytoprotective activity 
(as inhibition of endothelial cell apoptosis predominantly by small, 
dense HDL). (5) Vasodilatory activity (as stimulation of cellular NO 
and PGI2 production and inhibition of cellular superoxide release). 
(6) Anti-thrombotic activity (as inhibition of platelet aggregation 
predominantly by large, light HDL and enhanced anticoagulant 
activity by small, dense HDL). (7) Anti-infectious activity (as LPS 
binding). Inhibitory and stimulatory effects of HDL subpopulations 
are shown in red and green arrows, respectively.
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can accelerate the transfer of both cholesteryl ester hydro-
peroxides and phospholipid hydroperoxides [30]. Inactivation 
of oxidised lipids associated with HDL particles represents the 
second step in the capacity of HDL to protect from oxidative 
damage [28]. Lipid hydroperoxydes can thereby be reduced 
to the corresponding hydroxides by methionine residues 
of apoA-I, while short-chain oxidised phospholipids can be 
hydrolysed by HDL-associated enzymes PON1, PAF-AH and/
or LCAT [29,31].
HDL lipids, by modulating the rigidity of phospholipid 
monolayer of HDL particles, can signiÀ cantly modulate 
antioxidative activities displayed by the protein components. 
The surface monolayer rigidity of HDL is primarily determined 
by the relative content of such lipids as sphingomyelin (rela-
tive to phosphatidylcholine), free cholesterol, and saturated 
and monounsaturated fatty acids (relative to polyunsaturated 
fatty acids); increasing content of each of these components 
rigidiÀ es the surface monolayer of HDL and decreases the 
capacity of HDL to accept oxidised lipids and to inhibit LDL 
oxidation [28,32].
As a corollary, small, dense HDL, displaying enrichment 
in apoA-I relative to apoA-II, elevated activities of PON1, 
LCAT and PAF-AH activities and a low sphingomyelin/phos-
phatidylcholine ratio, display potent antioxidative activity 
as compared to large, light HDL [29].
Anti-inÁ ammatory activity
Low-grade local inÁ ammatory reaction is a prominent cha-
racteristic of atherogenesis [33]. Circulating HDL particles 
display multiple anti-inÁ ammatory actions which collectively 
may signiÀ cantly contribute to immunosuppresion of athe-
rosclerosis [34,35]. Indeed, HDL is capable of (i) decreasing 
cytokine-induced adhesion molecule expression on 
endothelial cells, (ii) inhibiting monocyte adhesion to the 
endothelium, (iii) acting directly on monocytes, inhibiting 
production of multiple pro-inÁ ammatory cytokines and 
chemokines and (iv) potently reducing neutrophil activa-
tion [36,37]. Intriguingly, lipid efÁ ux from cells mediated 
by ABCA1 and ABCG1 appears to form a mechanistic basis 
for several key pathways involved, including the capacity 
of HDL to decrease adhesion molecule expression and to 
inhibit monocyte and neutrophil activation [37]. Similarly 
to the antioxidative action, the anti-inÁ ammatory activity 
of HDL may also involve removal of oxidised lipids from 
endothelial cells and/or from oxidised LDL followed by 
their inactivation under the action of HDL-associated protein 
components PAF-AH, PON1 and LCAT [11,26]. The ability of 
HDL to inhibit adhesion molecule expression may be related 
to the presence of several protein and lipid components, 
which include apoA-I, apoA-II, apoA-IV and distinct molecular 
species of phospholipids, such as sphingosine-1-phosphate 
and sphingosylphosphorylcholine [38,39].
The potential heterogeneity of HDL anti-inÁ ammatory 
activity remains poorly characterised. Small, dense, protein-
rich HDL3 has been reported to be superior to large, light, 
lipid-rich HDL2 in terms of its capacity to inhibit vascular cell 
adhesion molecule 1 expression in endothelial cells [40], indi-
cative of enhanced intrinsic anti-inÁ ammatory properties of 
Cholesterol efÁ ux capacity
Cholesterol efÁ ux from macrophages, the primary cell type 
to accumulate cholesterol within atherosclerotic plaques, 
to HDL occurs via several mechanisms involving ABCA1 and 
ABCG1 transporters, the scavenger receptor class B type I 
(SR-BI) receptor and passive diffusion [4].
ABCA1 is central to lipid efÁ ux mediated by lipid-free/
lipid-poor apoA-I [16,17]. Experiments with cholesterol-
loaded mouse macrophages demonstrate that ABCA1 may 
account for at least 80% of cholesterol efÁ ux stimulated by 
cellular cholesterol loading [18]. Moreover, cholesterol efÁ ux 
from macrophages to apoB-depleted human sera with HDL-C 
levels in the range between the 25th and 75th percentiles is 
correlated with speciÀ c ABCA1-mediated efÁ ux [19]. Small 
discoid pre-E HDL particles, both initially present in HDL 
preparations and generated during remodelling of large HDL 
by macrophages, are key factors in this pathway. Formation 
of small, spherical, lipid-poor HDL ensues which may sub-
sequently mature to large, spherical, lipid-rich particles. 
Such HDL maturation involves interaction with other HDL 
receptors, primarily with ABCG1, and can be facilitated by 
apoE secreted from macrophages [20]; indeed, ABCG1 allows 
efÁ ux of cholesterol to mature spherical HDL2 and HDL3 par-
ticles [4]. Acting on large HDL, ABCG1 may form a sequential 
pathway of HDL biogenesis with ABCA1 and LCAT [21].
SR-BI may play an important role in the net cellular 
cholesterol efÁ ux, acting primarily in hepatocytes but equally 
in macrophages, adipocytes and other cell type [22,23]. 
Importantly, Cla-1 (human SR-BI) appears to provide a major 
contribution to cholesterol efÁ ux from macrophages under 
basal non-stimulated conditions when cellular cholesterol 
content is normal; such efÁ ux is ATP-independent and does 
not require energy supply [24]. It is however essential to keep 
in mind that cholesterol Á ux via SR-BI is always bidirectional; 
for this reason, SR-BI does not promote net cholesterol efÁ ux 
from cells to plasma HDL containing active LCAT, due to 
reuptake of cholesteryl ester into cells [25]. Passive receptor-
independent diffusion of cholesterol from plasma membranes 
to HDL particles, which involves direct interaction of HDL 
with the membrane surface, may equally provide signiÀ cant 
contribution to net cholesterol removal from cells [18].
Antioxidative activity
LDL oxidation is commonly considered to contribute to the 
initiation and progression of atherosclerosis [26]. Thus, LDL 
has long been thought to represent the major physiological 
target of protection from oxidative damage provided by 
HDL. The antioxidative activity of HDL is therefore typically 
measured in vitro as inhibition of LDL oxidation [26,27]. 
Removal of oxidised lipids from LDL or cells represents 
the À rst step of HDL-mediated protection from oxidative 
damage induced by free radicals [28]. Indeed, phospholipid 
hydroperoxides are rapidly transferred from oxidised LDL 
to HDL upon their co-incubation [29]. The transfer of lipid 
hydroperoxides from LDL to HDL can occur directly between 
lipoprotein phospholipid monolayers, either spontaneously 
or mediated by lipid transfer proteins, including CETP, which 
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the beneÀ cial effects on the endothelium [55]. Enhanced in 
NO bioavailability under the action of HDL may also reÁ ect 
antioxidative properties of HDL which involve reduced 
formation of superoxide anions and thereby prevent their 
reaction with NO to form peroxynitrate, a potent vascular 
oxidant [56]. It remains indeterminate as to whether the 
documented vasodilatory effects of HDL are speciÀ cally 
associated with individual HDL subpopulation(s).
Antithrombotic activity
Platelets are involved in the initiation, progression and 
rupture of atherosclerotic lesions [57].
HDL exerts multiple antithrombotic effects and may the-
reby beneÀ cially impact the progression of atherothrombotic 
disease [58]. First, HDL can decrease platelet aggregation 
as a result of enhanced production of NO which can be 
triggered by the interaction of HDL with platelet SR-BI [58]. 
Furthermore, HDL inhibits factors which promote blood 
coagulation, including tissue factors and factors X, Va and 
VIIIa [52]. Blood coagulation occurs through the formation of 
enzymatic protein complexes that assemble on the surface 
of anionic phospholipids. ApoA-I abrogates the pro-coagulant 
activity of anionic phospholipids, which lose their capacity 
to mediate activation of prothrombin by factor Xa in the 
presence of factor Va and to facilitate binding of factor 
Va [59].
Little is known to date of the potential association 
between such antithrombotic effects and individual HDL 
subpopulations. Large, light apoE-containing HDL2 particles 
appear to be more potent than small, dense HDL3 in terms 
of their capacity to inhibit platelet aggregation [60]. ApoE 
represents a potent inhibitory factor, accounting in part for 
the HDL action on platelet aggregation via activation of NO 
production. By contrast, tissue factor pathway inhibitor has 
been reported to be preferentially associated with dense 
subspecies of HDL in human plasma, resulting in potent 
anticoagulant activity of these particles [61]. Interestingly, 
post-translational modiÀ cations of apoA-I by protease activity 
are elevated in small, dense HDL, suggesting enrichment of 
this fraction in proteases [62].
Anti-infectious activity
Infections are thought to play a role in the progression and 
instability of atherosclerotic plaques, resulting in plaque rup-
ture, vessel constriction and occlusion of coronary arteries. 
LPS, a key functional component of the outer membrane of 
Gram-negative bacteria, is an important factor determining 
their pathogenicity [63]. Plasma HDL displays several key 
anti-infectious activities and thereby appears to form a part 
of the innate immune system.
First, HDL plays a major role in the binding of circulating 
LPS and its hepatic clearance to the bile and is thereby 
capable of inhibiting LPS-induced cellular activation [64]. 
The inactivation of LPS by HDL is mainly mediated by direct 
interaction with apoA-I and involves reduced expression of 
CD14, the major LPS receptor, on monocytes [65]. LBP and 
HDL3. This À nding is consistent with the potent antioxidative 
activity of small, dense HDL3 particles [29] and may reÁ ect 
their distinct proteome and/or lipidome [9]. Interestingly, 
a distinct particle subpopulation present in small, dense 
HDL exhibits potent immunomodulatory capacities towards 
neutrophils; factor H-related proteins quantitatively predo-
minate in these particles [41].
Cytoprotective activity
Apoptosis and necrosis of arterial wall cells, primarily of 
macrophages, induced by cellular accumulation of LDL-
derived non-oxidised and/or oxidised sterols, may signi-
À cantly contribute to the development of atherosclerotic 
plaques. HDL protects both macrophages and endothelial 
cells from apoptosis [42]. Major intracellular mechanisms 
underlying the anti-apoptotic actions of HDL include (i) 
cellular efÁ ux of oxidised cholesterol, primarily of 7-ketocho-
lesterol, mediated by ABCG1 [43], (ii) decreased intracellular 
generation of ROS [44], (iii) preservation of mitochondrial 
integrity [42], (iv) stimulation of NO synthesis by HDL inte-
raction with SR-BI [45] and (v) stimulation of endothelial 
cell migration by induction of intracellular signalling via S1P 
receptors [46]. Apolipoproteins A-I, E and J and together with 
minor bioactive lipids S1P, sphingosylphosphorylcholine and 
lysosulfatide represent two major groups of HDL components 
involved in cytoprotective effects of HDL [47-49].
The functional heterogeneity of cytoprotective properties 
of HDL remains poorly investigated. Small, dense, protein-
rich HDL3 particles display superior cytoprotective activity 
towards endothelial cells relative to large, light HDL2 [50]. 
Cytoprotective effects of HDL3 involve reduction of DNA 
fragmentation, annexin V binding and caspase-3 activation 
as well as decrease in cytoplasmic release of cytochrome c 
and of apoptosis-inducing factor. It is relevant in this regard 
that two components with potent cytoprotective properties, 
S1P and apoA-I, are enriched in small, dense HDL3c [50].
Vasodilatory activity
Endothelial function is usually deÀ ned as NO production 
and/or bioavailability. Endothelial dysfunction as a result 
of inactivation of NO by reactive oxygen species plays a 
pivotal role in the development, progression, and clinical 
complications of atherosclerosis and contributes to elevated 
risk of cardiovascular disease. Major mechanisms underlying 
endothelial dysfunction include pro-inÁ ammatory activation 
of endothelial cells, diminished function of endothelial 
progenitor cell function and endothelial cell apoptosis [51].
HDL particles display potent vasodilatory activity, which 
reÁ ects their capacity to stimulate NO release and prosta-
cyclin production by endothelial cells [52]. Improvement 
of NO bioavailability involves HDL binding to SR-BI and S1P 
receptors, which results in the activation of endothelial 
nitric oxide synthase [53,54]. HDL-mediated efÁ ux of cellular 
cholesterol and 7-oxysterols via ABCG1 can also improve 
formation of active eNOS dimers, resulting in decreased 
reactive oxygen species production which can contribute to 
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of the Caerphilly study [81]. Finally, both HDL2 and HDL3 
mass is related to cardiovascular risk in a prospective 29.1-
year follow-up of Gofman’s Livermore Cohort of 1905 men 
measured for lipoprotein mass concentrations by analytic 
ultracentrifugation between 1954 and 1957 [82]. A more 
consistent picture emerges when HDL particle heterogeneity 
is assessed by gel electrophoresis. Thus, plasma levels of 
large D1 HDL are consistently associated with protection 
from atherosclerosis [83-85]. In parallel, concentrations 
of small discoid HDL particles (the sum of apoA-I in pre-E1 
HDL and D4 HDL>25mg/dl) are often elevated in coronary 
heart disease patients, whereas large D2 HDL particles are 
decreased [84,86].
When HDL particles are separated by afÀ nity chroma-
tography, plasma levels of LpA-I are often [87,88], but not 
always [89,90], associated with protection from atheroscle-
rosis. The clinical signiÀ cance of LpA-I: A-II levels remains 
even more controversial [87-89]. Finally, when particle 
concentrations of HDL subfractions are assessed by NMR, 
levels of large HDL (size 9.4-14nm) typically display negative 
correlation with cardiovascular risk in univariate analyses, 
whereas concentrations of small HDL particles (7.3-8.2nm) 
show positive correlations [91-93]. The clinical relevance of 
circulating levels of individual HDL particle subpopulations to 
atherosclerosis and cardiovascular disease therefore remains 
unclear.
Functional deÀ ciency of HDL
HDL particles progressively lose normal biological activities 
and acquire altered properties as a result of alterations in 
HDL composition, structure and metabolism which are cha-
racteristic of dyslipidemia, insulin resistance, inÁ ammation, 
infection and cardiovascular disease [2]. Thus, HDL under-
goes dramatic modiÀ cation in structure and composition as a 
result of the concerted actions of the acute phase response 
and inÁ ammation. The association between inÁ ammation, 
oxidative stress, dyslipidemia and atherogenesis suggests 
that such HDL alterations may play a signiÀ cant role in 
the progression of cardiovascular disease. HDL has been 
proposed to possess “chameleon-like properties” [94]. In 
particular, HDLs become depleted in apoA-I, cholesteryl 
esters, PON1 and LCAT and enriched in free cholesterol, free 
fatty acids, sphingolipids, triglycerides and serum amyloid 
A, during the acute phase, displaying covalent modiÀ cations 
as a result of oxidation and/or glycation [2]. The decrease 
of apoA-I results from its replacement by serum amyloid A, 
which may become the major HDL apolipoprotein during the 
acute phase [2]. Together, modiÀ cations of HDL proteome 
and lipidome can reduce cellular cholesterol capacity 
as well as antioxidative and anti-inÁ ammatory activities 
of HDL particles [2]. By contrast, serum amyloid A, in a 
lipid-free or lipid-poor form, can also promote cholesterol 
efÁ ux via ABCA1, both by acting directly as an acceptor for 
cellular cholesterol and by increasing the availability of 
free cholesterol within the cell [95]. The susceptibility of 
speciÀ c HDL subpopulations to alterations during the acute 
phase and their functional implications remain however 
poorly investigated.
apoC-I are two other HDL-associated proteins involved in 
anti-infectious activities of HDL [66]. Moreover, HDL actions 
on LPS metabolism may depend on macrophage ABCA1, 
which participates in the removal of cell-associated LPS and 
restoration of normal macrophage responsiveness [67]. SR-BI 
may also be involved in the action of HDL on LPS, ensuring 
hepatic LPS clearance and glucocorticoid production [68].
Moreover, human plasma HDL is a major carrier of speciÀ c 
trypanosome lytic activity, which selectively protects humans 
from Trypanosoma brucei brucei, a parasitic species that 
causes sleeping sickness in livestock [69]. ApoL-I, a minor HDL 
apolipoprotein, constitutes a major functional component 
of the complex that ensures trypanosome killing [69] and 
also contains hemoglobin-binding protein, Hrp and apoA-I, 
which act cooperatively to achieve maximal killing capacity 
of the pathogen [70].
The both anti-infectious activities, the trypanosome-lytic 
and LPS-binding activities of human plasma, are associated 
with speciÀ c HDL subpopulations. The trypanosome-lytic 
factor is isolated from plasma as a minor subpopulation of 
large, dense HDL particles with molecular mass of 490kDa, 
particle diameter of 15-21nm and buoyant density of 
1.21-1.24g/ ml [71,72]. Another minor subpopulation of 
HDL accounts for the capacity of plasma to enhance CD14-
mediated cell adhesion of neutrophils in response to LPS. 
This HDL subset is small and dense, exhibiting a density of 
1.219-1.264g/ml and molecular mass of 200kDa [73]. Factor 
H-related proteins quantitatively predominate in these 
particles, which also contain apoA-I and LBP.
Novel aspects of HDL functionality
Recent data add new facets to the complex pattern of 
biological activities of HDL. Notably, human plasma HDL 
has been recently shown to improve glucose metabolism 
by multiple mechanisms which include enhanced insulin 
secretion by beta-cells as a result of improved cellular 
cholesterol homeostasis [74,75]. Another study has recently 
described a potent antielastase activity of HDL, which is 
observed as inhibition of extracellular matrix degradation, 
cell detachment, and apoptosis induced by elastase in human 
vascular smooth muscle cells [76]. Such a novel biological 
property of HDL can be accounted for by the presence in 
HDL of alpha-1-antitrypsin, a serpin peptidase inhibitor [8].
HDL subpopulations and atheroprotection
Evidence linking protection against cardiovascular disease 
to speciÀ c HDL subpopulations is conÁ icting. Discordance 
in these data partly reÁ ects complex relationships that 
exist between HDL subfractions separated by different 
methods. Thus, HDL2-C levels are inversely associated with 
coronary heart disease risk in the Kuopio Study [77] and 
Quebec City Suburbs Study [78]. By contrast, plasma levels 
of small HDL3-C are a strong and independent predictor 
of protection against atherosclerosis in the Physician’s 
Health Study [79], the 5-year follow-up of the Caerphilly 
and Speedwell study groups [80], and the 9-year follow-up 
264 L. Camont et al.
posed nomenclature, and relation to atherosclerotic cardio-
vascular events. Clin Chem 2011;57:392-410.
[8] Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, 
Cheung MC et al. Shotgun proteomics implicates protease inhi-
bition and complement activation in the antiinÁ ammatory pro-
perties of HDL. J Clin Invest 2007;117:746-56.
[9] Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, 
Kontush A. Proteomic analysis of deÀ ned HDL subpopulations 
reveals particle-speciÀ c protein clusters: relevance to antioxi-
dative function. Arterioscler Thromb Vasc Biol 2009;29:870-6.
[10] Kontush A, Therond P, Zerrad A, Couturier M, Négre-Salvayre A, 
de Souza JA et al. Preferential sphingosine-1-phosphate enrich-
ment and sphingomyelin depletion are key features of small 
dense HDL3 particles: relevance to antiapoptotic and antioxi-
dative activities. Arterioscler Thromb Vasc Biol 2007;27:1843-9.
[11] Kontush A, Chantepie S, Chapman MJ. Small, dense HDL par-
ticles exert potent protection of atherogenic LDL against oxi-
dative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8.
[12] Kontush A, Chapman MJ. Antiatherogenic small, dense HDL 
– guardian angel of the arterial wall? Nat Clin Pract Cardio-
vasc Med 2006;3:144-53.
[13] Heinecke JW. The HDL proteome: a marker-and perhaps media-
tor-of coronary artery disease. J. Lipid Res 2009;50:S167-71.
[14] Gordon S, Durairaj A, Lu JL, Davidson WS. High-Density Lipopro-
tein Proteomics: Identifying New Drug Targets and Biomarkers by 
Understanding Functionality. Curr Cardiovasc Risk Rep 2010;4:1-8.
[15] Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characteri-
zation of human plasma high density lipoprotein fractionated by 
gel À ltration chromatography. J Proteome Res 2010;9:5239-49.
[16] Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-
inducible apolipoprotein receptor that mediates cholesterol 
secretion from macrophages. J Biol Chem 2000;275:34508-11.
[17] Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J. 
Decreased cellular cholesterol efÁ ux is a common cause of 
familial hypoalphalipoproteinemia: role of the ABCA1 gene 
mutations. Atherosclerosis 2000;152:457-68.
[18] Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips 
MC et al. The roles of different pathways in the release of 
cholesterol from macrophages. J Lipid Res 2007;48:2453-62.
[19] De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, 
Rader DJ, Rothblat GH. The ability to promote efÁ ux via ABCA1 
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density lipoprotein cholesterol to remove cholesterol from 
macrophages. Arterioscler Thromb Vasc Biol 2010;30:796-801.
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Conclusions
HDL possesses several biological properties, in addition to 
cholesterol efÁ ux capacity, which may contribute to its 
antiatherogenic effects. These properties can be accounted 
for not only by apolipoproteins and enzymes but also by lipid 
components associated with HDL. HDL particles are highly 
heterogeneous in structure, composition and functionality. 
However, HDL can become functionally deÀ cient under 
conditions of inÁ ammation, atherogenic dyslipidemias and 
insulin resistance. Assessment of circulating levels of speciÀ c 
HDL subpopulations displaying distinct protein and/or lipid 
composition and biological activity holds promise to provide 
novel biomarkers of cardiovascular risk and to identify new 
therapeutic targets.
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